Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
01 March 2023 - 12:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Nick Colangelo, President and CEO will present at
the Canaccord Genuity Musculoskeletal Conference. The presentation
is scheduled to begin at 12:30 p.m. ET (9:30 a.m. PT) on Tuesday,
March 7, 2023.
A webcast of the presentation will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The Company markets two cell therapy products and one
specialty biologic product in the United States. MACI® (autologous
cultured chondrocytes on porcine collagen membrane) is an
autologous cellularized scaffold product indicated for the repair
of symptomatic, single or multiple full-thickness cartilage defects
of the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. The
Company also holds an exclusive license for North American rights
to NexoBrid® (anacaulase-bcdb), a biological orphan product
containing proteolytic enzymes, which is indicated for the removal
of eschar in adults with deep partial-thickness and/or
full-thickness burns. For more information, please
visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2023 Vericel
Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact: Julie
Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024